GLYC News
Archived Headlines
- GlycoMimetics drops IPO price to $8 and increases shares offered 01/07/14
- Orphan disease biotech GlycoMimetics revives IPO filing, removes original terms 12/20/13
- GlycoMimetics postpones $60 million IPO 11/08/13
- 15 US IPOs planned for the week of Nov 4 11/04/13
- Orphan disease biotech GlycoMimetics sets terms for $60 million IPO 10/28/13
See more
Hypertension biotech Bellerophon Therapeutics sets terms for $60 million IPO
Bellerophon Therapeutics, which is developing drug-device combination therapies for pulmonary and cardiac diseases, announced terms for its IPO on Tuesday. The Hampton, NJ-based company plans to raise $60 million by offering 4.0 million shares at a price range...read more
The 'NO' IPO: Nitric oxide biotech Bellerophon Therapeutics files for a $69 million IPO
Bellerophon Therapeutics, which is developing drug-device combination therapies for pulmonary and cardiac diseases, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering. Bellerophon was spun out of Ikaria in February 2014...read more
US IPO Recap: Twenty companies file or set terms for IPOs
The first full week of 2014 saw the most combined initial and terms filings since last June, while the first IPO of the year, by biotech GlycoMimetics (GLYC), posted a 13% gain. Four of the seven newly ...read more
GlycoMimetics prices upsized IPO at $8 per share
GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, raised $56 million by offering 7.0 million shares at $8, the lower revised price. The company upsized its IPO selling 22% more shares than previously anticipated (5.8...read more